<SEC-DOCUMENT>0001564590-20-044057.txt : 20200921
<SEC-HEADER>0001564590-20-044057.hdr.sgml : 20200921
<ACCEPTANCE-DATETIME>20200921091518
ACCESSION NUMBER:		0001564590-20-044057
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		4
CONFORMED PERIOD OF REPORT:	20200921
ITEM INFORMATION:		Regulation FD Disclosure
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20200921
DATE AS OF CHANGE:		20200921

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			JanOne Inc.
		CENTRAL INDEX KEY:			0000862861
		STANDARD INDUSTRIAL CLASSIFICATION:	RETAIL-HOME FURNITURE, FURNISHINGS & EQUIPMENT STORES [5700]
		IRS NUMBER:				411454591
		STATE OF INCORPORATION:			NV
		FISCAL YEAR END:			1228

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-19621
		FILM NUMBER:		201185322

	BUSINESS ADDRESS:	
		STREET 1:		325 E. WARM SPRINGS ROAD
		STREET 2:		SUITE 102
		CITY:			LAS VEGAS
		STATE:			NV
		ZIP:			89119
		BUSINESS PHONE:		702-997-5968

	MAIL ADDRESS:	
		STREET 1:		325 E. WARM SPRINGS ROAD
		STREET 2:		SUITE 102
		CITY:			LAS VEGAS
		STATE:			NV
		ZIP:			89119

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	APPLIANCE RECYCLING CENTERS OF AMERICA INC /MN
		DATE OF NAME CHANGE:	19930328
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>jan-8k_20200916.htm
<DESCRIPTION>8-K
<TEXT>
<!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
<head>
<title>
jan-8k_20200916.htm
</title>
</head>
<!-- NG Converter v5.0.2.50 -->
<body>

<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;border-top:Double 2.25pt;padding-top:1pt;text-indent:0%;font-weight:bold;;font-size:2pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:18pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">UNITED STATES<br />SECURITIES AND EXCHANGE COMMISSION<br /><font style="font-size:12pt;">WASHINGTON, D.C. 20549</font></p>
<p style="text-align:center;margin-top:9pt;line-height:4pt;border-bottom:Solid 1pt;padding-bottom:1pt;margin-bottom:0pt;margin-left:41.28%;margin-right:41.28%;text-indent:0%;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:9pt;text-indent:0%;font-weight:bold;font-size:18pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">FORM 8-K</p>
<p style="text-align:center;margin-top:9pt;line-height:4pt;border-bottom:Solid 1pt;padding-bottom:1pt;margin-bottom:0pt;margin-left:41.28%;margin-right:41.28%;text-indent:0%;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:9pt;text-indent:0%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">CURRENT REPORT</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Date of Report (Date of earliest event reported): September 21, 2020</p>
<p style="text-align:center;margin-top:9pt;line-height:4pt;border-bottom:Solid 1pt;padding-bottom:1pt;margin-bottom:0pt;margin-left:41.28%;margin-right:41.28%;text-indent:0%;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:18pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">JANONE&#160;INC.</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(Exact Name of Registrant as Specified in Charter)</p>
<p style="text-align:center;margin-top:9pt;line-height:4pt;border-bottom:Solid 0.75pt;padding-bottom:1pt;margin-bottom:0pt;margin-left:41.28%;margin-right:41.28%;text-indent:0%;font-size:6pt;">&nbsp;</p>
<p style="margin-top:9pt;line-height:4pt;margin-bottom:0pt;margin-right:41.28%;text-indent:0%;font-size:6pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top"  style="width:33%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Nevada</p></td>
<td valign="top"  style="width:33%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">000-19621</p></td>
<td valign="top"  style="width:34%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">41-1454591</p></td>
</tr>
<tr>
<td valign="top"  style="width:33%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:7.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(State or Other Jurisdiction</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:7.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">of Incorporation)</p></td>
<td valign="top"  style="width:33%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:7.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(Commission</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:7.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">File Number)</p></td>
<td valign="top"  style="width:34%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:7.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(IRS Employer</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:7.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Identification&#160;No.)</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top"  style="width:100%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">325 E. Warm Springs Road, Suite 102</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Las Vegas, NV 89119</p></td>
</tr>
<tr>
<td valign="top"  style="width:auto;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(Address of Principal Executive Offices and Zip Code)</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Registrant&#8217;s telephone number, including area code: 702-997-5968</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:7.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(Former Name or Former Address, if Changed Since Last Report)</p>
<p style="text-align:center;margin-top:9pt;line-height:4pt;border-bottom:Solid 1pt;padding-bottom:1pt;margin-bottom:0pt;margin-left:41.28%;margin-right:41.28%;text-indent:0%;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:9pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top"  style="width:6%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';"><font style="font-size:10pt;font-family:'Times New Roman'">&#9744;</font></p></td>
<td valign="top"  style="width:94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top"  style="width:6%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';"><font style="font-size:10pt;font-family:'Times New Roman'">&#9744;</font></p></td>
<td valign="top"  style="width:94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top"  style="width:6%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';"><font style="font-size:10pt;font-family:'Times New Roman'">&#9744;</font></p></td>
<td valign="top"  style="width:94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top"  style="width:6%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';"><font style="font-size:10pt;font-family:'Times New Roman'">&#9744;</font></p></td>
<td valign="top"  style="width:94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Securities registered pursuant to Section 12(b) of the Act:</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom"  style="width:35%; border-bottom:solid 1pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Title of each class</p></td>
<td valign="bottom"  style="width:1%; border-bottom:solid 1pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom"  style="width:20%; border-bottom:solid 1pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Trading</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Symbol(s)</p></td>
<td valign="bottom"  style="width:1%; border-bottom:solid 1pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom"  style="width:43%; border-bottom:solid 1pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Name of each exchange on which registered</p></td>
</tr>
<tr>
<td valign="bottom"  style="padding-left:10pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:35%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:-10pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Common Stock, $0.001 par value per share</p></td>
<td valign="bottom"  style="padding-left:10pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:-10pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom"  style="padding-left:10pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:20%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:-10pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">JAN</p></td>
<td valign="bottom"  style="padding-left:10pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:-10pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom"  style="width:43%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The NASDAQ Stock Market LLC </p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(The NASDAQ Capital Market)</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (&#167;230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (&#167;240.12b-2 of this chapter).</p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Emerging growth company&#160;&#160;&#160;<font style="font-family:'Times New Roman';"><font style="font-size:10pt;font-family:'Times New Roman'">&#9744;</font></font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.&#160; <font style="font-family:'Times New Roman';"><font style="font-size:10pt;font-family:'Times New Roman'">&#9744;</font></font></p>
<p style="margin-bottom:0pt;margin-top:0pt;border-bottom:Double 2.25pt;padding-bottom:1pt;text-indent:0%;font-size:4pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU2"></a><font style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Item 7.01.</font><font style="margin-left:36pt;">Regulation FD Disclosure</font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#212121;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="Background-color:#FFFFFF;">On September 21, 2020, JanOne Inc. (the &#8220;Company&#8221;) issued a letter to its stockholders providing an update on the Company. A copy of the letter is attached as Exhibit 99.1 to this Current Report on Form&#160;8-K. </font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="Background-color:#FFFFFF;">The furnishing of the attached letter is not an admission as to the materiality of any information therein. The information contained in the letter is summary information that is intended to be considered in the context of more complete information included in the Company&#8217;s filings with the the U.S. Securities and Exchange Commission (the &#8220;SEC&#8221;) and other public announcements that the Company has made and may make from time to time by press release or otherwise. The Company undertakes no duty or obligation to update or revise the information contained in this report, although it may do so from time to time as its management believes is appropriate. Any such updating may be made through the filing of other reports or documents with the SEC, through press releases, or through other public disclosures. </font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">This information is &#8220;furnished&#8221; and not &#8220;filed&#8221; for purposes of Section 18 of the Securities Exchange Act of 1934, or otherwise subject to the liabilities of that section. It may only be incorporated by reference in another filing under the Securities Exchange Act of 1934 or the Securities Act of 1933 only if and to the extent such subsequent filing specifically references the information incorporated by reference herein.</p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Item 9.01. Financial Statements and Exhibits</p>
<p style="margin-bottom:0pt;margin-top:6pt;margin-left:4.68%;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(d) &#160;&#160;&#160;&#160;&#160;&#160;&#160;Exhibits</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top"  style="width:10%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Exhibit</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Number</p></td>
<td valign="top"  style="width:1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:89%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Description</p></td>
</tr>
<tr>
<td valign="top"  style="width:10%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:6pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:89%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:6pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:10%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">99.1</p></td>
<td valign="top"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:89%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="jan-ex991_6.htm"><font style="text-decoration:none;">Letter to Stockholders</font></a></p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU3"></a><font style="text-decoration:underline;">SIGNATURES</font></p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.68%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Pursuant to the requirements of the Securities Exchange Act of 1934, we have duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<div align="right">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:35%;">
<tr>
<td colspan="2" valign="top"  style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">JanOne Inc.</p></td>
</tr>
<tr>
<td valign="top"  style="width:10.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;text-align:left;">&nbsp;</p></td>
<td valign="top"  style="width:89.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;text-align:left;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:auto; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">By:</p></td>
<td valign="top"  style="width:auto; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">/s/ Tony Isaac </p></td>
</tr>
<tr>
<td valign="top"  style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="width:auto; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Name:&#160;&#160;Tony Isaac</p></td>
</tr>
<tr>
<td valign="top"  style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Title:&#160;&#160;&#160;&#160;Chief Executive Officer</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Dated:&nbsp;&nbsp;September 21, 2020</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3</a></p></body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>jan-ex991_6.htm
<DESCRIPTION>EX-99.1
<TEXT>
<!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
<head>
<title>
jan-ex991_6.htm
</title>
</head>
<!-- NG Converter v5.0.2.50 -->
<body>

<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Exhibit 99.1</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><img src="g3tzensqqwrx000001.jpg" title="" alt="" style="width:176px;height:37px;"> <font style="margin-left:36pt;"></font>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="text-align:right;margin-bottom:8pt;margin-top:0pt;font-family:Franklin Gothic Book;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:6.85%;"><font style="margin-left:36pt;"></font>September 2020</p>
<p style="margin-bottom:8pt;margin-top:0pt;text-indent:0%;font-family:Franklin Gothic Book;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Dear Shareholder:</p>
<p style="margin-bottom:8pt;margin-top:0pt;text-indent:0%;font-family:Franklin Gothic Book;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">This past year has been an exciting time for our Company as we have transitioned into what we believe to be a flourishing biopharma company. The initial path forward is to continue the development of our worldwide exclusively licensed, proprietary, high-value, late-stage biopharma asset, JAN101, for the treatment of Peripheral Artery Disease, or PAD. We will also look for new indications for JAN101, like the recently announced potential application for the treatment of vascular complications associated with COVID-19, and novel ways to treat pain without the need for opioids.&nbsp;&nbsp;The biotechnology market demonstrated strong growth throughout most of 2020, with the NASDAQ Biotechnology Index growing by 44% from 2,961 on March 16, 2020, to 4,262 on August 31, 2020.</p>
<p style="margin-bottom:8pt;margin-top:0pt;text-indent:0%;font-family:Franklin Gothic Book;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><img src="g3tzensqqwrx000002.jpg" title="" alt="" style="width:388px;height:276px;">Our core biopharma asset can be applied to three identified and distinct markets that represent significant market opportunities: PAD, pain management, and COVID-19-related therapies. In 2018, the global market size for pain management pharmaceuticals was $38.9 billion and forecasted to reach $52.1 billion by 2024, exhibiting a CAGR of around 5% during 2019-2024.<sup style="font-size:85%;line-height:120%;vertical-align:top">1</sup><sup style="font-size:85%;line-height:120%;vertical-align:top"></sup> Specifically, the PAD market presents significant opportunity with expectations to reach approximately $5 billion by 2023<sup style="font-size:85%;line-height:120%;vertical-align:top">2</sup><sup style="font-size:85%;line-height:120%;vertical-align:top"></sup> at a CAGR of 6.8%. Further, according to the CardioVascular Coalition, patients are also at greater risk for heart attack and stroke. Studies have found that the total annual costs for patients with PAD exceed $21 billion, including nearly $10 billion for hospitalizations.<sup style="font-size:85%;line-height:120%;vertical-align:top">3</sup><sup style="font-size:85%;line-height:120%;vertical-align:top"></sup> Most recently, we have determined that our technology could have applications for COVID-19, an area that poses high immediate value to economies across the world. Combined, we believe JanOne is well positioned for success in the application of its patented core formulation component, sodium nitrite, for PAD and potential future product extensions.</p>
<p style="margin-bottom:8pt;margin-top:0pt;text-indent:0%;font-family:Franklin Gothic Book;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Over the past year, we have added substantial talent to our team, made progress with finalizing our Phase 2b PAD study protocols for FDA submission, and announced potential applications that address vascular complications relating to COVID-19. Collectively, these accomplishments contribute to a consistent increase in shareholder value and<font style="font-family:Calibri;"> we believe </font>move the company closer to a treatment for PAD, a potential opioid-free, non-addictive pain relief solution and a potential treatment for vascular complications resulting from COVID-19.&nbsp;&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-weight:bold;;">&nbsp;</p>
<div align="left"><table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:20%;"><tr><td style="width:20%;"></td></tr><tr><td valign="top"  style="border-bottom:Solid 1pt #000000;"><p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;text-indent:0pt;font-size:8pt;">&nbsp;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:0%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-size:8pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:8pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><sup style="font-size:85%;line-height:120%;vertical-align:top">1</sup>&nbsp;</font></p></td>
<td valign="top" style="width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;font-size:8pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> <font style="text-decoration:underline;">https://www.prnewswire.com/news-releases/global-52-1bn-pain-management-drugs-market-outlook-2019-2024--300877857.html</font> </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:0%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-size:8pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:8pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><sup style="font-size:85%;line-height:120%;vertical-align:top">2</sup>&nbsp;</font></p></td>
<td valign="top" style="width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;font-size:8pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> Allied Market Research, March 27, 2019</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:0%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-size:8pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:8pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><sup style="font-size:85%;line-height:120%;vertical-align:top">3</sup>&nbsp;</font></p></td>
<td valign="top" style="width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;font-size:8pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> <font style="text-decoration:underline;">https://cardiovascularcoalition.com</font><font style="font-size:9pt;text-decoration:underline;"> </font><font style="text-decoration:underline;"> /cardiovascular-care/peripheral-artery-disease-pad/</font></p></td></tr></table></div>
<p style="text-align:right;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#4472C4;text-transform:uppercase;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;font-variant: normal;">1</a><font style="text-transform:none;color:#000000;"> </font><font style="text-transform:none;margin-left:36pt;color:#000000;"></font><font style="font-size:9pt;text-transform:none;color:#000000;">JanOne Inc.</font></p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:9pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">325 East Warm Springs Road, Suite 102</p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:9pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Las Vegas, NV 89119</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:82.19%;text-indent:0%;font-size:9pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<font style="text-decoration:underline;">www.janone.com</font></p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Exhibit 99.1</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><img src="g3tzensqqwrx000001.jpg" title="" alt="" style="width:176px;height:37px;"> <font style="margin-left:36pt;"></font>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-weight:bold;;">&nbsp;</p>
<p style="margin-bottom:8pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Franklin Gothic Book;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">Recent Highlights</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.42%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:3.42%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:'Times New Roman';font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:11pt;"><font style="font-family:Franklin Gothic Book;">In January 2020, Dr. Amol Soin, one of the nation&#8217;s leading pain experts, joined JanOne as our Chief Medical Officer &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.42%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:3.42%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:'Times New Roman';font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:11pt;"><font style="font-family:Franklin Gothic Book;">In February 2020, we signed an agreement with CoreRx to conduct our Phase 2b clinical formulation and development.</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.42%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:3.42%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:'Times New Roman';font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:11pt;"><font style="font-family:Franklin Gothic Book;">In June 2020, we announced Dr. Doug Flanagan as Chief Formulation Advisor.&nbsp;&nbsp;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.42%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:3.42%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:'Times New Roman';font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:11pt;"><font style="font-family:Franklin Gothic Book;">In July 2020, the following individuals joined our Scientific Advisory Board:</font></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85%;text-indent:0%;font-family:Times New Roman;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85%;margin-right:8.18%;text-indent:0%;font-family:Franklin Gothic Book;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#9642; Dr. Rakesh Patel, an internationally recognized scientist in nitric oxide and redox biology, known for his work associated with blood flow regulation and pulmonary function.</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85%;margin-right:8.18%;text-indent:0%;font-family:Times New Roman;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85%;margin-right:8.18%;text-indent:0%;font-family:Franklin Gothic Book;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#9642; Dr. Timothy Ness, emeritus professor at University of Alabama at Birmingham, a pain mechanisms and medication expert who has served as a clinical research expert on pain for the National institutes of Health and the Food and Drug Administration.</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85%;margin-right:8.18%;text-indent:0%;font-family:Times New Roman;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85%;margin-right:8.18%;text-indent:0%;font-family:Franklin Gothic Book;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#9642; Dr. Alan Kaye, Chairman of the LSU Health New Orleans Anesthesiology Department and editor in chief of the journal <font style="font-style:italic;">Pain Physicians</font> and who serves on the FDA&#8217;s Advisory Board of Anesthetics and Analgesics.</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85%;margin-right:8.18%;text-indent:0%;font-family:Times New Roman;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85%;margin-right:8.18%;text-indent:0%;font-family:Franklin Gothic Book;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#9642; Dr. John Cooke, Chair of the Department of Cardiovascular Sciences at the Houston Methodist Research Institute, who, in his prior role, was recruited to spearhead the program in vascular biology at Stanford University and has served on national and international committees that deal with cardiovascular diseases.</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85%;text-indent:0%;font-family:Times New Roman;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.42%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:3.42%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:'Times New Roman';font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:11pt;"><font style="font-family:Franklin Gothic Book;">In July 2020, we received FDA authorization for the transfer of an investigational new drug application (IND) for our sodium nitrite tablets.</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.42%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:3.42%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:'Times New Roman';font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:11pt;"><font style="font-family:Franklin Gothic Book;">In August 2020, we completed stable formulation and engineering of JAN101 for GMP (Good Manufacturing Practice) manufacturing to support our planned Phase 2b PAD study.</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.42%;white-space:nowrap">
<p style="margin-top:0pt;margin-bottom:8pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:3.42%;white-space:nowrap">
<p style="margin-top:0pt;margin-bottom:8pt;font-family:'Times New Roman';font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-top:0pt;margin-bottom:8pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:11pt;"><font style="font-family:Franklin Gothic Book;">In August 2020, we selected Eurofins Alphora as our bottling and labelling partner to support upcoming clinical trials.</font></p></td></tr></table></div>
<p style="margin-bottom:8pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Franklin Gothic Book;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">A Safe Novel Treatment</p>
<p style="margin-bottom:8pt;margin-top:0pt;text-indent:0%;font-family:Franklin Gothic Book;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our drug candidate, JAN101, a sustained release of sodium nitrite, is a safe and novel treatment for improving vascular function, reducing neuropathic pain and other conditions resulting from poor blood flow. It is highly selective, acting only in damaged tissue. Sodium nitrite in sustained release promotes blood vessel growth and function, prevents tissue inflammation and necrosis, and prevents diabetic nephropathy, a leading cause of death in diabetics. Additionally, three human clinical studies have found that sodium nitrite significantly reduces pain.</p>
<p style="margin-bottom:8pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Franklin Gothic Book;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">Peripheral Artery Disease (PAD)</p>
<p style="text-align:right;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#4472C4;text-transform:uppercase;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;font-variant: normal;">2</a><font style="text-transform:none;color:#000000;"> </font><font style="text-transform:none;margin-left:36pt;color:#000000;"></font><font style="font-size:9pt;text-transform:none;color:#000000;">JanOne Inc.</font></p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:9pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">325 East Warm Springs Road, Suite 102</p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:9pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Las Vegas, NV 89119</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:82.19%;text-indent:0%;font-size:9pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<font style="text-decoration:underline;">www.janone.com</font></p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Exhibit 99.1</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><img src="g3tzensqqwrx000001.jpg" title="" alt="" style="width:176px;height:37px;"> <font style="margin-left:36pt;"></font>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="margin-bottom:8pt;margin-top:0pt;text-indent:0%;font-family:Franklin Gothic Book;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU2"></a><font style="font-family:Franklin Gothic Book;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our first drug candidate</font><font style="font-family:Franklin Gothic Book;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">,</font><font style="font-family:Franklin Gothic Book;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> JAN101 (formerly referred to as TV1001SR)</font><font style="font-family:Franklin Gothic Book;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">,</font><font style="font-family:Franklin Gothic Book;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> is intended to address the 8.5 million Americans who may have PAD. We expect to enter Phase 2b trials in early 2021 after promising results seen in </font><font style="font-family:Franklin Gothic Book;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">P</font><font style="font-family:Franklin Gothic Book;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">hase 1 and </font><font style="font-family:Franklin Gothic Book;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">P</font><font style="font-family:Franklin Gothic Book;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">hase 2a trials. One of the more encouraging outcomes from patients who participated in early trials was a reported reduction in associated PAD pain. </font><font style="font-family:Franklin Gothic Book;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">According to a Stanford University research study</font><font style="font-family:Franklin Gothic Book;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">,</font><font style="font-family:Franklin Gothic Book;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> up to 24% </font><font style="font-family:Franklin Gothic Book;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">of patients with PAD are at risk of high opioid use</font><font style="font-family:Franklin Gothic Book;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">.</font><sup style="font-size:85%;line-height:120%;vertical-align:top">4</sup><font style="font-family:Franklin Gothic Book;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><sup style="font-size:85%;line-height:120%;vertical-align:top"></sup></font><font style="font-family:Franklin Gothic Book;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> I</font><font style="font-family:Franklin Gothic Book;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">f JAN101 is successful, the potential increase in value to the medical community as a PAD treatment that also relieves associated pain without addictive properties could be significant. The US market opportunity as a PAD treatment that may also treat associated pain without addi</font><font style="font-family:Franklin Gothic Book;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">c</font><font style="font-family:Franklin Gothic Book;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">tive qualities could result in a potential multibillion-dollar revenue stream for </font><font style="font-family:Franklin Gothic Book;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">JanOne</font><font style="font-family:Franklin Gothic Book;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> if</font><font style="font-family:Franklin Gothic Book;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> JAN101 is</font><font style="font-family:Franklin Gothic Book;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> approved as a new drug by the FDA</font><font style="font-family:Franklin Gothic Book;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">.</font></p>
<p style="margin-bottom:8pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Franklin Gothic Book;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">COVID-19</p>
<p style="margin-bottom:8pt;margin-top:0pt;text-indent:0%;font-family:Franklin Gothic Book;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">A recent study in the <font style="font-style:italic;">New England Journal of Medicine</font> illustrated that SARS-CoV-2, the virus that causes COVID-19, damages the endothelial cells that line blood vessels that ultimately trigger blood clotting. This restricts and damages the vascular system of those infected with the virus. This illustrates that rather than treating COVID-19 as a respiratory condition, success may be achieved with treating the underlying vascular tissue damage caused by the attack of COVID-19 on endothelial cells. </p>
<p style="margin-bottom:8pt;margin-top:0pt;text-indent:0%;font-family:Franklin Gothic Book;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Based on the <font style="font-style:italic;">New England Journal of Medicine</font>&#8217;s research and various other ongoing studies that look at COVID-19 as a vascular disease, the Company&#8217;s sodium nitrite compound may prove to be a beneficial treatment for COVID-19. The Company is preparing its IND packages for FDA submission for continued development as a treatment of PAD and to extend JAN101 to potentially mitigate severe organ and tissue damage caused by COVID-19.</p>
<p style="margin-bottom:8pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Franklin Gothic Book;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">Robust Pipeline</p>
<p style="margin-bottom:8pt;margin-top:0pt;text-indent:0%;font-family:Franklin Gothic Book;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company has made a strategic decision to initially pursue Peripheral Artery Disease. Our planned pivotal Phase 2b PAD study is scheduled for early 2021. In this study, we will evaluate the efficacy of two doses (40 and 80 mg) of JAN101 to treat diabetic patients with PAD in a placebo-controlled, 12-week study. </p>
<p style="margin-bottom:8pt;margin-top:0pt;text-indent:0%;font-family:Franklin Gothic Book;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Plans are to study 300 diabetic adults with PAD in 3 cohorts of 100 patients each. The primary endpoint will be that the patient has the ability to walk without pain or muscle fatigue as a result of vascular function restored by our drug candidate. The secondary endpoints will be reduction in pain over the course of treatment, improved sensory nerve function and improved quality of life. </p>
<p style="margin-bottom:8pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Franklin Gothic Book;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">Experienced Management Team</p>
<p style="margin-bottom:8pt;margin-top:0pt;text-indent:0%;font-family:Franklin Gothic Book;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">One of our greatest assets is the team that has been carefully and strategically assembled to advance JanOne. The decades of experience in business and science of the team provide us with a depth of knowledge and contacts to efficiently and effectively move JAN101 forward and identify and develop new applications.&nbsp;&nbsp;</p>
<p style="margin-bottom:8pt;margin-top:0pt;text-indent:0%;font-family:Franklin Gothic Book;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU3"></a>As a director of JanOne since May 2015 and CEO since May 2016, I have spearheaded the successful turnaround of the company and its transition into biotechnology.&nbsp;&nbsp;I have invested in various companies, both private and public, since 1980.&nbsp;&nbsp;I serve as a director of Live Ventures Incorporated (Nasdaq: LIVE), a holding company for diversified businesses, since December 2011.&nbsp;&nbsp;I am the Chairman and Co-founder of Isaac </p>
<div align="left"><table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:20%;"><tr><td style="width:20%;"></td></tr><tr><td valign="top"  style="border-bottom:Solid 1pt #000000;"><p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;text-indent:0pt;font-size:8pt;">&nbsp;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:0%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-size:8pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:8pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><sup style="font-size:85%;line-height:120%;vertical-align:top">4</sup>&nbsp;</font></p></td>
<td valign="top" style="width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;font-size:8pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> <font style="text-decoration:underline;">https://pubmed.ncbi.nlm.nih.gov/30922747/</font></p></td></tr></table></div>
<p style="text-align:right;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#4472C4;text-transform:uppercase;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;font-variant: normal;">3<font style="text-transform:none;color:#000000;"> </font><font style="text-transform:none;margin-left:36pt;color:#000000;"></font><font style="font-size:9pt;text-transform:none;color:#000000;">JanOne Inc.</font></p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:9pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">325 East Warm Springs Road, Suite 102</p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:9pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Las Vegas, NV 89119</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:82.19%;text-indent:0%;font-size:9pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<font style="text-decoration:underline;">www.janone.com</font></p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Exhibit 99.1</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><img src="g3tzensqqwrx000001.jpg" title="" alt="" style="width:176px;height:37px;"> <font style="margin-left:36pt;"></font>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="margin-bottom:8pt;margin-top:0pt;font-family:Franklin Gothic Book;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Franklin Gothic Book;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Organization</font><font style="font-family:Franklin Gothic Book;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">. </font><font style="font-family:Franklin Gothic Book;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> I am a graduate of Ottawa University in 1981, where I majored in Commerce and Business Administration and Economics.</font></p>
<p style="margin-bottom:8pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Franklin Gothic Book;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">Tony Giordano, Ph.D., Chief Scientific Officer<font style="font-weight:normal;"> &#8211; Dr. Giordano has held senior management positions at eight biotechnology companies, including four that moved drug discovery efforts into early-stage clinical trials. As CEO of TheraVasc, he was responsible for the development of TV1001 our leading asset now known as JAN101,  Most recently, he served as Senior Director of Special Projects in the Innovations group at the Cleveland Clinic, an American academic medical center ranked #2 as best hospital in the world by </font><font style="font-style:italic;font-weight:normal;">U.S. News &amp; World Report</font><font style="font-weight:normal;">. Dr. Giordano has secured over $6M in federal funding for companies he has managed. He previously held positions as a senior scientist at Abbott Laboratories, Staff Fellow at NIA, and Biotech Fellow at NCI.</font></p>
<p style="margin-bottom:8pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Franklin Gothic Book;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">Amol Soin, MD, Chief Medical Officer<font style="font-weight:normal;"> &#8211; Dr. Soin has been recognized as one of America&#8217;s Top Doctors and is the recipient of the Patient's Choice Award, an honor given only to the top 1% of physicians in the country. Dr. Soin is founder of The Ohio Pain Clinic, a network of free-standing chronic pain management facilities in southwestern Ohio focused on non-opioid-based treatments for chronic pain. Dr. Soin was appointed by Governor Kasich to the Ohio Medical Board in 2012 to two 5-year terms and has served as the Ohio Medical Board&#8217;s president, during which time he was instrumental in passing statewide rules and guidelines to help the opioid crisis. Dr. Soin is a nationally recognized speaker and author of the book </font><font style="font-style:italic;font-weight:normal;">Curing</font><font style="font-weight:normal;"> </font><font style="font-style:italic;font-weight:normal;">America</font><font style="font-weight:normal;">. He has authored a range of research papers, publications, and abstracts and served as a primary investigator for various clinical research initiatives. Presently, Dr. Soin serves as the State of Ohio&#8217;s Medicare Care Advisory Committee&#8217;s Pain Management Representative and serves on the prescription drug abuse committee and legislative task force for the Ohio State Medical Association.</font></p>
<p style="margin-bottom:8pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Franklin Gothic Book;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">Doug Flanagan, Ph.D., Chief Formulation Advisor <font style="font-weight:normal;">-- Dr. Flanagan was engaged by JanOne to work on its proprietary sustained release formulation, and he currently works closely with CoreRx to ensure chemical formulation compliance. He brings us over 40 years of scientific, pharmaceutical formulation and clinical experience and has published over 90 peer-reviewed articles and delivered over 150 presentations, talks and lectures around the world. He has lent his formulation expertise to over 50 pharmaceutical companies and medical organizations, including Abbott Laboratories, Pfizer Animal Health (spun off as Zoetis), Bristol Myers Squibb, the World Health Organization and the Food and Drug Administration, to name a few. Dr. Flanagan also holds various formulation patents, including pharmaceutical formulations of nitrite, a key component of JAN101. Dr. Flanagan was appointed as Emeritus Professor at the University of Iowa College of Pharmacy, where he served as a faculty member for 34 years.</font></p>
<p style="margin-bottom:8pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Franklin Gothic Book;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">Michael Stein, Legal Counsel<font style="font-weight:normal;"> </font>and Corporate Secretary<font style="font-weight:normal;"> &#8211; Mr. Stein joined the company in October 2017. Mr. Stein also serves as Senior Vice President and General Counsel for Live Ventures Incorporated (Nasdaq: LIVE). Prior to joining JanOne, Mr. Stein was a corporate partner at DLA Piper LLP from April 2016 through October 2017, and an associate from 2005 through 2012, where he gained biotechnology transaction experience. Prior to rejoining DLA, Mr. Stein worked at Caesars Entertainment Corporation (Nasdaq: CZR) and at Everi Holdings Inc. (NYSE: EVRI). Mr. Stein holds a JD from the University of Maryland, and an MS and BS in Accounting from the University of Florida.</font></p>
<p style="margin-bottom:8pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Franklin Gothic Book;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU4"></a>Virland Johnson, CFO<font style="font-weight:normal;"> &#8211; Mr. Johnson was appointed Chief Financial Officer of the Company in 2017. In addition to his role as CFO for JanOne, he also serves as CFO for Live Ventures Incorporated (Nasdaq: LIVE). Prior to joining JanOne, Mr. Johnson was Senior Director of Revenue for JDA Software from February 2010 to April 2016, where he was responsible for revenue recognition determination and sales and contract support while acting as a </font></p>
<p style="text-align:right;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#4472C4;text-transform:uppercase;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;font-variant: normal;">4<font style="text-transform:none;color:#000000;"> </font><font style="text-transform:none;margin-left:36pt;color:#000000;"></font><font style="font-size:9pt;text-transform:none;color:#000000;">JanOne Inc.</font></p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:9pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">325 East Warm Springs Road, Suite 102</p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:9pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Las Vegas, NV 89119</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:82.19%;text-indent:0%;font-size:9pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<font style="text-decoration:underline;">www.janone.com</font></p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Exhibit 99.1</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><img src="g3tzensqqwrx000001.jpg" title="" alt="" style="width:176px;height:37px;"> <font style="margin-left:36pt;"></font>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="margin-bottom:8pt;margin-top:0pt;font-weight:bold;font-family:Franklin Gothic Book;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:normal;">subject matter expert. Prior to joining JDA, Mr. Johnson provided leadership and strategic direction while serving in C-</font><font style="font-weight:normal;">l</font><font style="font-weight:normal;">evel executive roles in public and private companies such as Cultural Experiences Abroad, Inc., Fender Musical Instruments Corp., Triumph Group, Inc., Unitech Industries, Inc. and Younger Brothers Group, Inc. Mr. Johnson&#8217;s more than 25 years of experience is primarily in SEC and financial reporting</font><font style="font-weight:normal;">.</font><font style="font-weight:normal;"> Mr. Johnson holds a </font><font style="font-weight:normal;">b</font><font style="font-weight:normal;">achelor&#8217;s degree in Accountancy from Arizona State University. </font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-weight:bold;;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-weight:bold;;">&nbsp;</p>
<p style="margin-bottom:8pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Franklin Gothic Book;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">Scientific Advisory Board</p>
<p style="margin-bottom:8pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Franklin Gothic Book;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">Chris Kevil, Ph.D., Chair of the Scientific Advisory Board<font style="font-weight:normal;"> &#8211; Dr. Kevil, an internationally known expert in vascular pathophysiology, PAD, and nitric oxide biology, discovered the role of sodium nitrite in promoting angiogenesis that led to the development of TV1001, now known as JAN101. Dr. Kevil earned his Ph.D. from LSU Health Shreveport in Molecular and Cellular Physiology, followed by a fellowship at the University of Alabama at Birmingham (UAB) with an emphasis on redox pathophysiology. Returning to LSU Health Shreveport in the Department of Pathology, he established cutting-edge research programs regarding redox biology regulation of peripheral vascular diseases. This led to groundbreaking insights on how glutathione, nitrite/nitric oxide, and hydrogen sulfide regulate vascular health during ischemia. </font></p>
<p style="margin-bottom:8pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Franklin Gothic Book;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">Edgar Ross,<font style="font-weight:normal;"> </font>MD<font style="font-weight:normal;"> &#8211; Dr. Ross is the current Director of the Pain Management Center at Brigham and Women&#8217;s Hospital and a professor of anesthesia at Harvard Medical School. Dr. Ross is recognized as one of Castle Connolly Top Doctors for the fifth year in a row. In addition to serving as chairman of Pfizer&#8217;s partnership on pain, Dr. Ross also has served as a member of the Blue Cross and Blue Shield Opioid Prescribing Policy Committee.</font></p>
<p style="margin-bottom:8pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Franklin Gothic Book;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">Rakesh Patel, Ph.D.<font style="font-weight:normal;"> &#8211; Dr. Patel is currently Vice Chair for Research, Department of Pathology, and Director of the Center for Free Radical Biology at the University of Alabama at Birmingham (UAB). Most noted is his research to understand the molecular basis of nitric oxide, and nitrite interactions with organs and red blood cells. Dr. Patel is also known for his work to understand the impacts on the biological process associated with blood flow regulation and pulmonary function.</font></p>
<p style="margin-bottom:8pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Franklin Gothic Book;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">Timothy Ness, MD, Ph.D<font style="font-weight:normal;">. &#8211; Dr. Ness is Professor Emeritus and former Pain Treatment Division Chief, Director of Pain Research and Vice Chair for Clinical Research in the Department of Anesthesiology and Perioperative Medicine at the University of Alabama at Birmingham (UAB). He has served as a clinical research expert on pain for the National Institutes of Health (NIH), Food and Drug Administration (FDA) advisory panels, the Veterans Administration (VA), and various international research institutes. He has served on the American Pain Society and the American Society of Regional Anesthesia and Pain Medicine Board of Directors. He is currently funded by the NIH.</font></p>
<p style="margin-bottom:8pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Franklin Gothic Book;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU5"></a>Alan Kaye, MD, Ph.D., DABA, DABPM, DABIPP<font style="font-weight:normal;"> &#8211; Dr. Kaye has been the Professor and Chairman of the Department of Anesthesiology at LSU Health Sciences Center in New Orleans since January 2005. Before that, he was Professor and Chairman of the Texas Tech University Health Sciences Center&#8217;s Department of Anesthesiology in Lubbock, Texas. Prior to that, he was the Medical Director of the Greater New Orleans Surgical Center, the Director of Resident Recruitment, Acting Program Director and an Attending Staff of the Department of Anesthesiology at Tulane University Medical Center in New Orleans. He received two BS degrees and a MD degree from the University of Arizona. He also completed a pain management fellowship at Texas Tech Health </font></p>
<p style="text-align:right;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#4472C4;text-transform:uppercase;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;font-variant: normal;">5<font style="text-transform:none;color:#000000;"> </font><font style="text-transform:none;margin-left:36pt;color:#000000;"></font><font style="font-size:9pt;text-transform:none;color:#000000;">JanOne Inc.</font></p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:9pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">325 East Warm Springs Road, Suite 102</p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:9pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Las Vegas, NV 89119</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:82.19%;text-indent:0%;font-size:9pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<font style="text-decoration:underline;">www.janone.com</font></p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Exhibit 99.1</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><img src="g3tzensqqwrx000001.jpg" title="" alt="" style="width:176px;height:37px;"> <font style="margin-left:36pt;"></font>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="margin-bottom:8pt;margin-top:0pt;font-weight:bold;font-family:Franklin Gothic Book;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:normal;">Sciences Center. He is </font><font style="font-weight:normal;">b</font><font style="font-weight:normal;">oard </font><font style="font-weight:normal;">c</font><font style="font-weight:normal;">ertified as a Consultant in Anesthesiology and has a special certificate in Pain Management for the American Board of Anesthesiology. He is also a Diplomate of the American Board of Pain Medicine and the American Board of Interventional Pain Physicians. He has authored or co-authored over 150 abstracts and 200 manuscripts and book chapters in the fields of pulmonary vascular pharmacology and anesthesiology. He serves on a number of national committees</font><font style="font-weight:normal;">,</font><font style="font-weight:normal;"> including </font><font style="font-weight:normal;">the</font><font style="font-weight:normal;"> National Board of Directors of ASIPP and ABIPP. He is editor</font><font style="font-weight:normal;"> </font><font style="font-weight:normal;">in</font><font style="font-weight:normal;"> </font><font style="font-weight:normal;">chief of the journal </font><font style="font-style:italic;font-weight:normal;">Pain Physicians</font><font style="font-weight:normal;"> and is on the FDA Advisory Board on Anesthetics and Analgesics. He was an Associate National Board Examiner in Anesthesiology</font><font style="font-weight:normal;">.</font></p>
<p style="margin-bottom:8pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Franklin Gothic Book;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">John Cooke, MD, Ph.D.<font style="font-weight:normal;"> &#8211; Dr. Cooke is the Chair of the Department of Cardiovascular Sciences at the Houston Methodist Research Institute, Director of the Center for Cardiovascular Regeneration, and Medical Director of the RNA Therapeutics Program in the Houston Methodist DeBakey Heart and Vascular Center in Houston, Texas. He trained in cardiovascular medicine and obtained a Ph.D. in physiology at the Mayo Clinic. He was recruited to Harvard Medical School as an assistant professor of medicine. In 1990, he was recruited to Stanford University to spearhead the program in vascular biology and medicine, and he was appointed professor in the Division of Cardiovascular Medicine at Stanford University School of Medicine, and associate director of the Stanford Cardiovascular Institute until his recruitment to Houston Methodist in 2013. Dr. Cooke has published over 500 research papers, position papers, reviews, book chapters and patents in the arena of vascular medicine and biology, with over 30,000 citations. He has served on national and international committees that deal with cardiovascular diseases, including the American Heart Association, American College of Cardiology, Society for Vascular Medicine, and the National Heart, Lung, and Blood Institute. He has served as president of the Society for Vascular Medicine, as a director of the American Board of Vascular Medicine, and as an associate editor of </font><font style="font-style:italic;font-weight:normal;">Vascular Medicine</font><font style="font-weight:normal;">.</font></p>
<p style="margin-bottom:8pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Franklin Gothic Book;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">A Bright Future Ahead</p>
<p style="margin-bottom:8pt;margin-top:0pt;text-indent:0%;font-family:Franklin Gothic Book;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We feel strongly that the targeted indication areas of potentially treating PAD, pain management and treating vascular complications of COVID-19 represent promising treatment areas for our proprietary drug platform. We believe that the pivotal Phase 2b study for PAD and the IND submission for the COVID-19 protocol are compelling upcoming catalysts for the advancement of our high-value late-stage biopharma asset. We have assembled a world-class team of scientific and clinical experts in vascular disease and pain management that are leading the future success of our Company. We believe the continued development of our intellectual property and the potential value that JanOne brings to patients will gain recognition from investors and the medical community alike.&nbsp;&nbsp;</p>
<p style="margin-bottom:8pt;margin-top:0pt;text-indent:0%;font-family:Franklin Gothic Book;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Thank you for your confidence in our Company, and we look forward to making a difference in millions of lives in the future.</p>
<p style="margin-bottom:8pt;margin-top:0pt;text-indent:0%;font-family:Franklin Gothic Book;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p>
<p style="margin-bottom:8pt;margin-top:0pt;text-indent:0%;font-family:Franklin Gothic Book;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Sincerely,</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Franklin Gothic Book;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Tony Isaac</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-style:italic;font-family:Franklin Gothic Book;font-size:11pt;font-weight:normal;text-transform:none;font-variant: normal;">Chief Executive Officer</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&nbsp;</p>
<p style="text-align:right;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#4472C4;text-transform:uppercase;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;font-variant: normal;">6</a><font style="text-transform:none;color:#000000;"> </font><font style="text-transform:none;margin-left:36pt;color:#000000;"></font><font style="font-size:9pt;text-transform:none;color:#000000;">JanOne Inc.</font></p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:9pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">325 East Warm Springs Road, Suite 102</p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:9pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Las Vegas, NV 89119</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:82.19%;text-indent:0%;font-size:9pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<font style="text-decoration:underline;">www.janone.com</font></p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Exhibit 99.1</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><img src="g3tzensqqwrx000001.jpg" title="" alt="" style="width:176px;height:37px;"> <font style="margin-left:36pt;"></font>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:8pt;margin-top:0pt;text-indent:0%;color:#0F0F0F;font-family:Franklin Gothic Book;font-weight:bold;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;"><font style="Background-color:#FFFFFF;">Forward-Looking and Cautionary Statements</font></p>
<p style="text-align:justify;margin-bottom:8pt;margin-top:0pt;text-indent:0%;color:#0F0F0F;font-size:7pt;font-family:Franklin Gothic Book;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="Background-color:#FFFFFF;">This press release contains &#8220;forward-looking statements&#8221; within the meaning of the Private Securities Litigation Reform Act of 1995. In accordance with the safe harbor provisions of this Act, statements contained herein that look forward in time that include everything other than historical information, including statements relating to (i) </font><font style="color:#000000;">whether JAN101 can treat vascular complications in COVID-19 patients, (ii) whether the company can obtain FDA approval for its COVID-19 study, (iii) when the Phase 2b trials for PAD commence, and (iv) when and whether the company will submit an IND for the treatment of COVID-19 vascular complications, and (v) when manufacturing of JAN101 will commence</font><font style="Background-color:#FFFFFF;">. These forward-looking statements can be identified by terminology such as &#8220;will,&#8221; &#8220;aims,&#8221; &#8220;expects,&#8221; &#8220;anticipates,&#8221; &#8220;future,&#8221; &#8220;intends,&#8221; &#8220;plans,&#8221; &#8220;believes,&#8221; &#8220;estimates&#8221; and similar statements. JanOne may also make written or oral forward-looking statements in its periodic reports to the U.S. Securities and Exchange Commission (the &#8220;SEC&#8221;) on Forms 10-K and 10-Q, Current Reports on Form 8-K, in its annual report to stockholders, in press releases, and other written materials and in oral statements made by its officers, directors or employees to third parties. There can be no assurance that such statements will prove to be accurate, and there are a number of important factors that could cause actual results to differ materially from those expressed in any forward-looking statements made by the company, including, but not limited to, plans and objectives of management for future operations or products, the market acceptance or future success of our products, and our future financial performance. The company cautions that these forward-looking statements are further qualified by other factors including, but not limited to, those set forth in the company&#8217;s Annual Report on Form 10-K for the fiscal year ended December 28, 2019 (available at http://www.sec.gov). JanOne undertakes no obligation to publicly update or revise any statements in this release, whether as a result of new information, future events, or otherwise.</font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="text-align:right;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#4472C4;text-transform:uppercase;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;font-variant: normal;">7</a><font style="text-transform:none;color:#000000;"> </font><font style="text-transform:none;margin-left:36pt;color:#000000;"></font><font style="font-size:9pt;text-transform:none;color:#000000;">JanOne Inc.</font></p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:9pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">325 East Warm Springs Road, Suite 102</p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:9pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Las Vegas, NV 89119</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:82.19%;text-indent:0%;font-size:9pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<font style="text-decoration:underline;">www.janone.com</font></p></body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>g3tzensqqwrx000001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g3tzensqqwrx000001.jpg
M_]C_X  02D9)1@ ! 0$ E@"6  #_X0%V17AI9@  34T *@    @ $ #^  0
M   !      $   0    !   !X $!  0    !    90$"  ,    $    S@$#
M  ,    !  4   $&  ,    !  (   $1  0    1    U@$5  ,    !  0
M  $6  0    !    !@$7  0    1   !&@$:  4    !   !7@$;  4    !
M   !9@$<  ,    !  $   $H  ,    !  (   $]  ,    !  (   %2  ,
M   !  (         "  (  @ "     @   %F   #UP  !>$   C>   .H@
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M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R_\  $0@
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MX"=)<T=4<71117KG %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MHQTX+M^=>6U]_@*[KX:%26[_ $T/E\335.M*"'Q123S)##&TDLC!41%RS$\
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MO$Y;B</'FG'3NM2:6+HU7RQ>I4\8^!K'Q19O)$D5MJB_-'<A<>8< ;9,<D8
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M]^#725PUYJ4M#[G(<'6PV&:JJS;O;Y=0KR[5?^0Q>_\ 7Q)_Z$:]1KR[5?\
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M;W5;**( X>!7E).?1@O&,\Y_"O1_#G@_1_"Z,=/A9KAUVO<S-ND89SCT Z=
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MWMO/;(Q5IHI R*0 2"PXR 0?QKRITJD/CBUZH[8SC+X7<L45E?\ "4>'L?\
M(>TO_P "X_\ &N;U+XK^&[.'-FT]_*5;:L<1101T#%\8!]0#T/'KK3PF(J.T
M(-_(B=>E!7E)'<UY]XV^)5OHQN-+T@^=J2_(\^ 8X#W'^TP].@)YZ%:\_P#$
MGQ%UOQ#$UMN6RLRS9BMRP+J>-KMGYA@XQP#Z=,<C7OX'(^5J>(^[_/\ R/+Q
M.8W7+2^\?++)/,\TTC22R,6=W.68GDDD]33***^C/)-;PO\ \C=HO_7_  ?^
MC%KZ9KY@T&YALO$6F75P^R""[BDD;!.U5<$G YZ"O=/^%E^$/^@O_P"2TO\
M\37S6>T*M6I!TXMZ=$V>OEM6$(2YFD=8/O#ZU\R^*/\ D;M:_P"O^?\ ]&-7
MMP^)?A#(_P")O_Y+2_\ Q->%Z]<PWOB+4[JW??!/=RR1M@C<K.2#@\]#1D5"
MK2J3=2+6G5-!F56$X1Y6F9]%%%?2GD'T)\-?^2>Z7_VU_P#1KUU=>9^!_''A
MS1_!UA87^H^3=1>9O3R)&QF1B.0I'0BNA_X65X0_Z"__ )+2_P#Q-?#8O"8B
M6(J-4VTV^C[GTE"O25**<ELNJ[')_&K_ )@7TG_]IUY/7H7Q0\2Z1XB_LG^R
MKO[1Y'G>9^Z=-N[9C[P&>AKSVOJ<JA*&$A&:L]=_5GBXV2E7DXNZT_(WO"?B
M>[\+ZS'=0NQM795NH0,B1,^F1\PR<'^A(/T/IVIV.KV:W>GW45S V/FC;.TX
M!P1U!P1P>1FOEJM;0/$FJ>&KQKC3;CR]^!+&PW)( <X8?F,C!&3@C-89EE:Q
M7OPTE^?J:X3&NC[LM4?3-+FO.]!^+>DWD.S68VT^X5>9$5I(G/'3 + DD\$$
M #[QKJXO%GAR:%)5UW3@KJ& >Y56P?4$Y!]CS7RM7!8BD[3@SVH8BE-7C)&@
MEC9Q7LE[':0)=RKMDG6,"1QQP6ZD<#\A5G)JG>:MING[/MNHVEMOSL\^94W8
MQG&3SU'YUE7OCGPOI_E^=K=JV_./()FZ8Z[ <=>_6LXTJM2W+%OY-ERG"&[2
M.@KQ;XL>'[*PU5-4M;BW26[(\^S! <,<_O O]T[3DXZ^N>+^N_&)GA,.@V31
M,R\W%V 67K]U 2,C@@DD=05KS*^OKK4[Z:]O9GFN)FW/(W4G^@[ #@"OH<IR
M[$4:GM9^ZNW<\K'8NE.')'7S*]%%%?2'D!1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
-10 4444 %%%% '__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>4
<FILENAME>g3tzensqqwrx000002.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g3tzensqqwrx000002.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" .-!/P# 2(  A$! Q$!_\0
M'P   04! 0$! 0$           $" P0%!@<("0H+_\0 M1   @$# P($ P4%
M! 0   %] 0(#  01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T? D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$!
M 0$! 0        $" P0%!@<("0H+_\0 M1$  @$"! 0#! <%! 0  0)W  $"
M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#W^BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHJM>:A9Z=%YM[<Q6\
M?]Z1@HH LT5D6_BG0+N416^L64LAZ*DP)K7ZC(H **** "BBL+Q=KDOAWPY<
MZE#$LKPJ2%;H: -VBN)^&OC6Z\;Z%)?W5M';NLA3:A)%=M0 4444 %%%% !1
M110 454OM3L=,C$E]=PVZ'@-*X45G?\ "9^&?^@[8?\ ?]: -RBL,>,_#1(
MUVPR>!^_6MF*6.>)98G5XV&593D&@!]%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%4KK5].L9XX+J]@AED.$1W +?2K@((!!R#TH 6BBB
M@ HHHH **** "BBB@ HJE?:OIVFL@OKV"W+G"B5PN:MI(DL:O&P9&&00>#0
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M-\4^.6\/>(-+TY($E2]8C?GI0!VM%0QW4$DGEK*ADQDJ&YJ:@ HHHH ****
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MO[<\4ZI=2>>=T2))T'XUZE\2?"9\6^%9K.(9G7YH_J*\@\(?$O5/AT/^$?\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M:1-YNG:5:VTG]Z*, UKT4 %9M[X?TC4KE+F]TZWGFC.4>1,D5I44 (JA%"J
M%'  I:** ,W4O#VCZP0=1TZWNB.GFH#4>G>&-#TB3S-/TJUMG/\ %'& :UJ*
M "J]Y8VNH0&"[@CGB/5'7(JQ10!A6W@OPS9W"SV^AV44JG(=8@"*W0 !@=!1
M10!E:EX:T76'#ZCIEM=,.AEC!-36&B:7I=NT%C806\3C#)&F :OT4 4=/T;3
M=*,AL+*&V,AR_EKC<?>I+[3;+4X/)OK6*XB/\,BY%6J* ,&V\%>&;.836VAV
M44BG(98@"*W0 H  P!T I:* (;JTM[V!H+J%)HFZHXR#65:>#O#EA<BXM-&L
MX9@<ATC -;=% %34-+L-5A\F_M(KF/\ NR+D5FVG@SPW8S+-:Z)90R+T9(@"
M*W:*    8'04444 %%%% !1110 5E:EX9T36)/,U'2[6Y<=Y8P36K10!D:?X
M6T'29O-L-)M+:3^]'& :UZ** "L:^\)>']2F,M[H]I/(>K21@FMFB@#*T[PW
MHND/OT[3+:V8]XHP*U:** "LW4] TG6=O]I:?;W6WIYJ9Q6E10!SG_" >$O^
MA>T__OR*OZ?X;T726W:?IEM;'UCC K4HH *S=3\/:/K)4ZEIUO=;>GFH#BM*
MB@#.TW0=*TA&33M/M[97&&$2 9IUCHFF:;/+-96,$$LIS(T:X+?6K]% %>\L
M;34(#!>6\<\1ZHZY%9$'@CPO;3":'0K&.0'(98AD5OT4 (JJBA5 "@8 ':AE
M5U*L RD8(/>EHH P)O _A>XF,TVA6+R$Y+&(9-:]I96MA (+2".&(=$1< 58
MHH **** *>H:3I^JQ>7?V<-PG]V1<UF6_@GPQ:3+-;Z'8QR+R&6( BM^B@!%
M4*H50 !T JIJ&E6&K0^3J%I#<Q_W95R*N44 9&G>%]"TB;SM.TJUMI/[T48!
MJPNAZ6FI'45L(!>GK.$^;\ZOT4 ,FACN(FBF17C88*L,@U@GP+X5,OFG0;'S
M,YW>4,YKH:* (H+>&UA6&"-8XUZ*HP!4M%% &)>^$/#NI3F>\T:SGE/5GC!-
M7M.T?3M)B\O3[*&V0]HDQ5VB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HIDDB0Q-)(P5%&23V%4M*UK3];MS/IURL\0."R^M &A1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M?#/PG)X3\*PVUR!]LD&Z8@=Z[.@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH @O+R"PM)+JYD6.*-2S,QKRN7XX6=S=R0Z3H][=K&<%TCR#]*ZOXG6
M%WJ7@.^M[(,93AL+UP.M4/A9!HC^"[+[-!;^>B[9SM&[=D]: ,0_&&\[^&-1
M_P"_-=WX1\12>)=(^VRV,UFV\KY<JX/%:_V:S_YXP_\ ?(J6-(T7$:JJ^BCB
M@!]%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 97
MB.PO=3T2>TT^Y%M<2# D*[L#OQ7D%M\&/$UE--+:^)_*,S;G"QX&?IFO9]6U
M.#2-+GOK@XCB4L?>O#EU[XG>/KJ6\\.-_9^FAL+N8#(]>10!I_\ "J?&7_0V
MM_WQ_P#7KT;P3H.H^'M%^R:GJ!O9MY;S",<5Y1-J'Q6\#.-2U>0:GIZ</&&!
MP/7@5[)X8\0V_B;0X-2MQ@2#YE_NMW% &Q1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "L;Q5IM
MYJ_AVZLK"X^SW$JX20=JV:Y/QV_BA-/@/A=$:?<?,W-CB@"E9>%=<C^'G]B2
M:J?[2)_X^L=.:XW_ (59XU_Z&QO^^#_C2?:?C#_SPA_[^#_"C[3\8/\ GA#_
M -_!_A0 O_"K/&O_ $-C?]\'_&O1O!.A:GX?T7[)JFH?;9]Y;S,8XKSC[3\8
M?^>$/_?P?X5Z-X(?Q$^B9\2HJWN\\*V>.U '34444 %%%% !12$A5)8@ =2:
MC@NK>Z0M;S1RJ.I1@10!+1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MN81-#<H\9Z,#Q4GV^U_Y[+1S1[A=%FBJWV^U_P">RT?;[7_GLM/F7<+HLT5
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MD;!CIVZ5T]% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M:;7$<X4444 :^D_ZV7Z"M6LK2?\ 6R_05JUUTO@1O#8****T*"BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MK0!-17F\WQ0EBF9/[-0X./\ 6&H_^%J2_P#0,3_OX:P^LTNYG[6)Z917F?\
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MK5K*TG_6R_05JUUTO@1O#8****T*"BBB@ HHHH **** "BBB@ HHHH ****
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MU6P44450R:WZM^%=*OW%^E<U;]6_"NE7[B_2NBAU-*8M%%%;FH4444 %%%%
M!1110 4444 (WW37-7'^L_SZUTK?=-<U<?ZS_/K7/7Z&=0AHHHK R"KNG?\
M'S%]35*KNG?\?,7U-5'XD..YOT445VG0%%%% !1110 4444 %%%% !5;4/\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !7A'BS_ )#]U_UT/]:]WKPCQ9_R'[K_ *Z'^M<F
M,^%&-;8PJ***\XY@JSIO_(6M/^NE5JLZ;_R%K3_KI36X'L'\*_[HI*7^%?\
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ML_Y#]U_UT/\ 6O=Z\(\6?\A^Z_ZZ'^M<F,^%&-;8PJ***\XY@JSIO_(6M/\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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ME\Z".4*5#J&P>V:DKA?A_K/B>Z22P\2Z<;>>!0%D&,,/PKNJ "BBB@ HHHH
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MJV"BBBJ&36_5OPKI5^XOTKFK?JWX5TJ_<7Z5T4.II3%HHHK<U"BBB@ HHHH
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M^>A_[Z_^M1Y%[_ST/_?7_P!:@#1KP?Q81_;]W_UT/]:]G\B]_P">C?\ ??\
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MY%[_ ,]#_P!]_P#UJWA'EC8TBK*QHT5G>1>_\]#_ -]?_6I1!>\_O#[?/_\
M6JAFA12+D(H;DXYI: "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** .&^(-KXJQ;7_AB4&2$8> Y
MP_/I7 VWQ6\=7T\FF6V@"34HCMEVQ\*:]WKC_#?@R71/$VJ:Q+=I*;UV8*%Q
MM!.: .<^'WP^U2RUR?Q-XCG674+CE4&?W?MS7J=%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MN0H08# 5UOC#Q%'X7\-7>IN5WQH?+#="U>6?$S2YO"OCG3?%E@"L<LH2XVC
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MS'I3_!GQ%UX>*/\ A&?%UH(KZ3_5R*H4?E0!ZU17 ?%/QAJ/@_2+>]L#&,R
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M#UNBLKQ!K2Z%H\U]Y33,JY2->K'TKRZ;7_BQJ4+7^G:;':V[#='#+&&8CZT
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M-_ZY5XWX[\=:[XKT233(_#%['^\!W>0W8UT?@'Q]K"II^AW/AR[A1%VF9H6
M'- 'LE%':B@ J*ZMTN[66WD *2(58'T(J6@]* /G;P+X6M(_C%J$+'?#:,S1
MH>@(->Z>)'DB\-W[PCYUA.T"O,?!VFW\'Q>UJYFLYDMW+[9&0A3SZUZ_/"EQ
M!)#(,HZX(H ^=OA=?^+[:POY-"T>*[629M\CRA3G<?6MOQ?I7Q%\96,%G=:#
M#"L<JOO\]3C!JNEOXN^%?B"\EL-/.HZ1=/N$2 L5[]!6S;?$CQCK]_#9:=X:
M>V5F&^:=63:.^,T =Y;W<?A?P1!)K95?LT.) >>1VKC+'X@>*_$D3S^&O#2-
M8HQ596E"[A]#76>-O#=SXG\%3:89-MRR9R#U;%><>%?&NN^$-$.@7/AJYDN;
M8E(GCB8H_;)- %#PS-JT_P :C)K5JMK>%1F-6SV]16Q\;88[C7O#T4HW(9!D
M?\"%9WA:R\37/Q:&K:W8/$)@"I12548]:W?B]IU]>^(- >TM)ITCD^=HT)"_
M,.M 'JNGQ)#I\$<2A45  !VJS4-J"+2($8(4<5-0 C,J*68@*!DD]J\2\9^(
M+OXC:\OA+P_N-DC_ .EW(Z'':MKXRZUXCM-*2PT*TGD%QQ)+"A8@?A7&>#?&
M%[X.TD6EMX2O9)FYEF-NV6- 'N7AS0+3PUHEOIEFH$<2X)]36K7!^"O'FH>)
M[Z2"\T2XL549#R1LH/YUWE !1110!SWC?2K?5_"5_;W !58F<''0@5YE\ ]$
M@@M]0OG/F3K*8U8]A7KNOH\GA_4$C4L[0. H').*\]^"UA>V.DWZWEK+ S7!
M($BD9% %SXV3S0_#^Y\G/S<-C\*YCP9J7C^U\)V46E^'X)+4#*/YZC=^%>J>
M*M"C\1^';O37 S*F%)[&O']#\2^-/AU"=$O]$EU&VC8^5+$K,0/PH GO?#7C
MOQ%XTTW6+_2(K5;9AN99@3C->E>,_%^G>$=)6ZOT66=N(HL9+-7,>%_&/C#Q
M5K:!M%_L_34^^\H96;\#3_B]X0O]>L+74=.'F7%BXD$/]_% %4^*_B#J^G&[
MLO#$4=K*F5W3C.,>AK*^!AF-_K)N%$<Y?YT'0')JS#\2/$5WHL6EV/AJXCU+
MR_*+21,L:X&,YH^"NEZMIU[JQU:UDBGD;<692 <D]#0!GW%K!=?M _OT#[ 2
MH/T%>YUXW_9M_P#\+V:\^QS?9=K?OMAV]/6O9* "L;Q#X6TKQ3:K;:K TL2G
M( <K_*MFO*/$GB'QUX3UR:XBT\:GIDGW$7)9?P% &9XW^$.DZ/I3:UX<+V5W
M9CS!EBV['UKK/A-XLN_%?A437QW7$)V,V/O5PFN>-/%_CBT.A:?X=FLUN.))
MI49<#OUKT_X?^$E\'>&(-/+;IB-TI_VJ .JHHHH *\K^.>BP7WA'[:WRSP.
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MAGPVO_&]IX1B&BZ%#<6K2,?-,P4L<^E6O$V@?$'QAJ&FR7FB0VXM95;>)E)
M!R:KZ3>^,OA7<W&FMI3ZGICR%HC&"Q0$Y[5TFC^/?&/B?5XK:V\/FRM0P,DT
MRLIQWQF@#MM=U^R\*^&%O=7VGRTQM(SN;'2N+M/&WCG7K07NC>&(ULV_U;/.
M 6'8X-;?Q6\(W/BWPF;>T;_2('\U5S]X@=*Y/1OB-X@T_08-'7PQ<_VC;H($
M)B;RS@8SF@#/^%3WTGQ)UE]1A$%T0-\:G('6I_B!:PWGQBT*.= Z $X/KD4[
MX7:9K]OX_P!5N];LWBDF56WA3MY[ U=\9:;?S_%W1;F&SFDMT5MTBH2HZ=Z
M/80 JA5  '0"EHHH "<#)[5X-XC9OB!\8K328W+66FG<Q XSUKUWQ=J=SI'A
MB]O+2WDGG1,)'&N22>.E<'\%O#5W96%YK>J12)?7TF[;*N&4<T >K(BQHJ*
M%48 %.HHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH 3 ]*6BB@ P#U%%%% !1110 4444 )@>@HP/2EHH **
M** "BBB@ HHHH *,444 %)@>E+10 4444 %%%% !28'H*6B@ P/2BBB@ HHH
MH **** "BBB@ HHHH 3 SG%+110 4444 %%%% !@>E%%% !1110 4444 %%%
M% !@>E%%% !1@#H*** "BBB@ HHHH **** "BBB@ HHHH **** "C ]*** "
MCKUHHH **** "BBB@ HP/2BB@ HHHH **** "BBB@ HHHH ,#THHHH 3 /44
MM%% !1110 4444 &!Z4444 %%%% !1110 4444 %%%% !28&<XI:* "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MD5K6GP.\,W^CV[R7&H%I(@V#/QG'I6!X-N=2^'OQ$_X1*67S--G.8L\D9YH
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M"MN3ZTSXE>"=5O\ 5;/Q+H&'U*S(Q$1G=@YI-"^+@74H=&\4:=+INH-@&23
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MVP;S-R]2!7J=175O'=VLEO*H:.12K ^E 'C6M?$<S?"BU%L__$SNE%L%!Y#
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MLLI=&AWWL< (C88)XZ<UQ]]\89[C27TV\\,SR:@R^6\1!*[NF>F*]M"A1@
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M.6@C)]2@H XSP/XNUCQ9/)<W&D-8V 'R%SDL>U=Q2*BH,*H4>@&*6@ HHHH
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M>,'TXZ;9L"%A]<C%>UTBJJ#"J%'H!BEH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M>P9GQWY!&#C@BHOC?X9U,Q)X@_X2:\;3[N[@CBTLAO*A8KC>/GQG@G[HZ]:
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M$_2MWP#X]N-1^&UYKGB @W.E--'=.BX\SRQG.!P"0<<<9H ]%HKPO0M(\?\
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M]U8V]Q)!) \L:NT4@PR$C.T^XH GHHHH **** "BBB@ HHHH **** "BBB@
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M "1W5O\ KVB_]"6H5^"?@Z+PY-H\,-U'YSH\EZ)%-P2IR!N92 /4  5UNO\
MANT\1^&;C0;R6=+6>-8W>)E#X!!X)!';TH \8^)>GO/\'/!.HM$TUI9+;FY0
M$XV-&!DXYZC&?]JNOTWX7_"C5M)35++3;>:R9-YF749]JC&3N/F<$=P>E=];
M:'8V_AR'0I(_M-A';+:E+@!O,0+M^;C!X]J\\G_9\\$S7_VE&U."+=G[-'<C
MR_IEE+8_X%0!<^&Z> X[C7+CP7I=S$+9O(GN-\CQSXR0(RSL#^G4>M84'A+X
M;?%B2YU72VNM-U,3-YZPN(I=X_B:,[A@]<@#/.3G->KZ-HNF^'M+BTW2;2.U
MM(ONQI^I)/)/N>:XOQ-\%?"'B?49+^6&ZL;J5MTKV,@02'N2K*PS[@#- '&V
MMWXD^''Q)T/P^_BR3Q%8ZFXCDMK@DRP G /+,5QG(P0#@\5[K7$^$?A3X6\&
M70O=/MII[Y00MU=R;W4'K@ !1]0,UVU 'C7Q;E70_B1X(\27>?[.@F,4SD96
M/Y@<_7!)_P" UZ3X@\5Z7X>\,3Z]/=0R6J1>9#MD&)SCY54\YR<=,^M6];T/
M3?$>DS:9JUJES:38W(Q(Y'0@CD$>HKS_ $[X ^"K#4UO'%_>*K;A;7,RF+VR
M%4$CV)/OF@#G_BKJ%SX@^'/A;Q>=.DMHH;Q+F6V=MY1&Z$\#(.!V_B%>OVFO
MZ3?:(FLPZA;'3VC\PW!D 11C^(GICOGI5JZL+2^L)+"ZMHIK25/+>%U!5E],
M5YE)^SYX)DU#[2IU..+=G[*MR/+^F2I?'_ J */PE/\ ;?Q#\:^*+4'^S;B<
M0P. 0LISG(_  _\  JM^$O\ DX'QI_UZ1?RCKTO2=(T_0]-AT[3+6.UM(1A(
MXQ@#W]S[GFLO3O!VGZ9XPU3Q/#-=->ZC&L<T;LIC4+C&T!<C[HZDT <I\>/^
M293?]?<'_H54_C<ZQ_#K2W<X5;^W))[#::[SQ;X5L?&6A-I&HRW$5NTB2%K=
ME5\J<CE@1C\*GUOPYIGB+09-&U2#S[.10""<,".A!'0B@#1MY8Y[:*6)UDC=
M RNIR&!'!!KROX*_\?7C7_L-R?S-;_@KX5Z%X$U2XU#2KK4)99XO*9;F1&4+
MD'C:@.>/6MCPOX.T_P )R:H]A-=2'4KIKJ;SV4[7/9<*,#GOF@#B/"7_ "<#
MXT_Z](OY1U<^/'_),IO^ON#_ -"KJ].\':?IGC#5/$\,UTU[J,:QS1NRF-0N
M,;0%R/NCJ34OBWPK8^,M";2-1EN(K=I$D+6[*KY4Y'+ C'X4 <A\8+C3HOA;
MY&HVLEQ]I>*&WV.$\N4C*N6.< 8.>.>G?-<[9^!?BQ<Z/#I3^.]/&DO$(V>$
MF24)CH'\L,W'^V*TOC=J1LM)T+1;F3[/HFH7(BO[LP"5HT7:1MR#AL9.0,_+
MQ7,#X:?!V6(3Q^.F1=N0/[4M@?R*9S0!Z!J?@2'1/@UJGAC1O-E<6DC!C]^:
M3[Q)^N,8],"N)^%O@?X<>+_"%K)=:;%/K,0*7D?VV97# G#% XP",<@8JQ\*
M;W['\1]4\/Z!KMWK7AF*T\T2SG(BER!A3@>IZ  ^^,UU/B/X(^#_ !)J,E^\
M5W87$K%Y38RJBR,>I*LK 'Z 4 9NDZ%\+M'^)-GH^C:1*^NP*9Q+!<32QVY
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M%\OZ?,I;]:Z.T^&'AO3M7T74=-@ELI-)5UACA8;9=PP3)N!9CSUR* .9O_\
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MOPMXZO\ 3K:V7S5L[J0%)F]!C"DGL"AS7J?@+7KKQ-X'TK6+V)8[FXBS(%&
M2"5W =@<9Q[UQMA^SYX*LKM9YFU.]4'/DW%PH0_]\*I_6NS\3>"]*\4^&!X>
MN?.M;!2A1;,JA0)]T#*D ?A0!T5%9V@Z+;>'=!LM'M'E>WM(Q%&TQ!<@>I
MS^%:- !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110!5U'3+'5[)[/4;."[MG^]
M%/&'4_@:XQO@O\/6E\P^'4W9S@74X'Y;\5WM% &?H^A:3X?M/LND:?;64).6
M6",+N/J3U)]S6A110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110!5BTRP@U";4(K&VCO9U"RW*1*)) .@9L9(X'7TJ
MU110!7O;&SU*T>TO[2"ZMI,;X9XPZ-@Y&5/!YJ6**.&)(HD6.-%"HB# 4#H
M.PI]% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
/ %%%% !1110 4444 ?_9

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
